SCA2 predictive testing in Cuba: challenging concepts and protocol evolution

• Published in: Journal of community genetics 2015-07, Vol.6 (3), p.265-273
• Main Authors: Cruz-Mariño, Tania, Vázquez-Mojena, Yaimeé, Velázquez-Pérez, Luis, González-Zaldívar, Yanetza, Aguilera-Rodríguez, Raúl, Velázquez-Santos, Miguel, Estupiñán-Rodríguez, Annelié, Laffita-Mesa, José Miguel, Almaguer-Mederos, Luis E., Paneque, Milena
• Format: Article
• Language: English
• Subjects: Biomedical and Life Sciences; Biomedicine; Epidemiology; Gene Function; Gene Therapy; Human Genetics; Original; Original Article; Public Health
• ISSN: 1868-310X; 1868-6001
• DOI: 10.1007/s12687-015-0226-4

Spinocerebellar ataxia type 2 (SCA2) is a neurodegenerative disease caused by a CAG repeat expansion in the ATXN2 gene. Cuba has the highest prevalence (6.57 cases/10 5 inhabitants) of SCA2 in the world. The existence of 753 affected individuals and 7173 relatives at risk prompted the development in 2001 of the first predictive testing program in the country. The medical records of over 1193 individuals, who requested the test within a 13-year period, were analyzed retrospectively. The presymptomatic and the prenatal tests had uptake rates of 43.4 and 23.9 %, respectively. Several ethical challenges resulted from this program. These include the following: (1) withdrawal due to the initial protocol’s length; (2) the request to participate by 16 at-risk adolescents; (3) the decision made by ten out of 33 couples with a test-positive fetus to carry the pregnancy to term, leading to de facto predictive testing of minors; (4) the elevated frequency of the ATXN2 gene large normal alleles (≥23 to 31 repeats) in the reference population. These issues have led to major changes in the guidelines of the predictive testing protocol: (1) the protocol length was shortened; (2) the inclusion criteria were expanded to reach at-risk adolescents with an interest in prenatal diagnosis; (3) interdisciplinary follow-up was offered to families in which test-positive fetuses were not aborted; (4) prenatal testing was made available to carriers of large normal alleles with ≥27 CAG repeats. The profiles of the participants were similar to those reported for other predictive testing programs for conditions like Huntington disease and familial adenomatous polyposis. The genetic counseling practices at the community level, the ample health education provided to the at-risk population, together with multidisciplinary and specialized attention to the affected families, are lessons from the Cuban experience that can be relevant for other international teams conducting predictive testing for other late-onset neurodegenerative disorders.